General MedicationsORALStandard

VENLAFAXINE BESYLATE

Standard Dose

EQ 112.5MG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview VENLAFAXINE BESYLATE is listed in Drugs@FDA under application 215429 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient VENLAFAXINE BESYLATE Form and strength TABLET, EXTENDED RELEASE;ORAL - EQ 112.5MG BASE Sponsor ALMATICA Submission history Latest submission status date: 2023-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview VENLAFAXINE BESYLATE is listed in Drugs@FDA under application 215429 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient VENLAFAXINE BESYLATE Form and strength TABLET, EXTENDED RELEASE;ORAL - EQ 112.5MG BASE Sponsor ALMATICA Submission history Latest submission status date: 2023-08-18 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.